Global Plasma-derived Therapies 麻豆原创 Research Report 2023

Publication ID:

PB510235008

Publication Date:

October 9, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Plasma-derived therapeutics start from human blood plasma instead of the chemical or synthetic materials from which most pharmaceuticals are made.
The global Plasma-derived Therapies market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Plasma-derived Therapies market research.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Plasma-derived Therapies market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols
Segment by Type
Albumin
Immunoglobulin
Factor VIII
Others
Segment by Application
Hemophilia
Primary Immunodeficiencies (PIDs)
Idiopathic Thrombocytopenic Purpura (ITP)
COVID-19
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Plasma-derived Therapies report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Plasma-derived Therapies 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Albumin
1.2.3 Immunoglobulin
1.2.4 Factor VIII
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Plasma-derived Therapies 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hemophilia
1.3.3 Primary Immunodeficiencies (PIDs)
1.3.4 Idiopathic Thrombocytopenic Purpura (ITP)
1.3.5 COVID-19
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Plasma-derived Therapies 麻豆原创 Perspective (2018-2029)
2.2 Plasma-derived Therapies Growth Trends by Region
2.2.1 Global Plasma-derived Therapies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Plasma-derived Therapies Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Plasma-derived Therapies Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Plasma-derived Therapies 麻豆原创 Dynamics
2.3.1 Plasma-derived Therapies Industry Trends
2.3.2 Plasma-derived Therapies 麻豆原创 Drivers
2.3.3 Plasma-derived Therapies 麻豆原创 Challenges
2.3.4 Plasma-derived Therapies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Plasma-derived Therapies Players by Revenue
3.1.1 Global Top Plasma-derived Therapies Players by Revenue (2018-2023)
3.1.2 Global Plasma-derived Therapies Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Plasma-derived Therapies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Plasma-derived Therapies Revenue
3.4 Global Plasma-derived Therapies 麻豆原创 Concentration Ratio
3.4.1 Global Plasma-derived Therapies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Plasma-derived Therapies Revenue in 2022
3.5 Plasma-derived Therapies Key Players Head office and Area Served
3.6 Key Players Plasma-derived Therapies Product Solution and Service
3.7 Date of Enter into Plasma-derived Therapies 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Plasma-derived Therapies Breakdown Data by Type
4.1 Global Plasma-derived Therapies Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Plasma-derived Therapies Forecasted 麻豆原创 Size by Type (2024-2029)
5 Plasma-derived Therapies Breakdown Data by Application
5.1 Global Plasma-derived Therapies Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Plasma-derived Therapies Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Plasma-derived Therapies 麻豆原创 Size (2018-2029)
6.2 North America Plasma-derived Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Plasma-derived Therapies 麻豆原创 Size by Country (2018-2023)
6.4 North America Plasma-derived Therapies 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Plasma-derived Therapies 麻豆原创 Size (2018-2029)
7.2 Europe Plasma-derived Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Plasma-derived Therapies 麻豆原创 Size by Country (2018-2023)
7.4 Europe Plasma-derived Therapies 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Plasma-derived Therapies 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Plasma-derived Therapies 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Plasma-derived Therapies 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Plasma-derived Therapies 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Plasma-derived Therapies 麻豆原创 Size (2018-2029)
9.2 Latin America Plasma-derived Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Plasma-derived Therapies 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Plasma-derived Therapies 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Plasma-derived Therapies 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Plasma-derived Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Plasma-derived Therapies 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Plasma-derived Therapies 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CSL Behring LLC
11.1.1 CSL Behring LLC Company Detail
11.1.2 CSL Behring LLC Business Overview
11.1.3 CSL Behring LLC Plasma-derived Therapies Introduction
11.1.4 CSL Behring LLC Revenue in Plasma-derived Therapies Business (2018-2023)
11.1.5 CSL Behring LLC Recent Development
11.2 Shire
11.2.1 Shire Company Detail
11.2.2 Shire Business Overview
11.2.3 Shire Plasma-derived Therapies Introduction
11.2.4 Shire Revenue in Plasma-derived Therapies Business (2018-2023)
11.2.5 Shire Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Plasma-derived Therapies Introduction
11.3.4 Bayer Revenue in Plasma-derived Therapies Business (2018-2023)
11.3.5 Bayer Recent Development
11.4 Kedrion
11.4.1 Kedrion Company Detail
11.4.2 Kedrion Business Overview
11.4.3 Kedrion Plasma-derived Therapies Introduction
11.4.4 Kedrion Revenue in Plasma-derived Therapies Business (2018-2023)
11.4.5 Kedrion Recent Development
11.5 Takeda
11.5.1 Takeda Company Detail
11.5.2 Takeda Business Overview
11.5.3 Takeda Plasma-derived Therapies Introduction
11.5.4 Takeda Revenue in Plasma-derived Therapies Business (2018-2023)
11.5.5 Takeda Recent Development
11.6 Biotest
11.6.1 Biotest Company Detail
11.6.2 Biotest Business Overview
11.6.3 Biotest Plasma-derived Therapies Introduction
11.6.4 Biotest Revenue in Plasma-derived Therapies Business (2018-2023)
11.6.5 Biotest Recent Development
11.7 Octaparma
11.7.1 Octaparma Company Detail
11.7.2 Octaparma Business Overview
11.7.3 Octaparma Plasma-derived Therapies Introduction
11.7.4 Octaparma Revenue in Plasma-derived Therapies Business (2018-2023)
11.7.5 Octaparma Recent Development
11.8 Bio Products Laboratory (BPL)
11.8.1 Bio Products Laboratory (BPL) Company Detail
11.8.2 Bio Products Laboratory (BPL) Business Overview
11.8.3 Bio Products Laboratory (BPL) Plasma-derived Therapies Introduction
11.8.4 Bio Products Laboratory (BPL) Revenue in Plasma-derived Therapies Business (2018-2023)
11.8.5 Bio Products Laboratory (BPL) Recent Development
11.9 LFB
11.9.1 LFB Company Detail
11.9.2 LFB Business Overview
11.9.3 LFB Plasma-derived Therapies Introduction
11.9.4 LFB Revenue in Plasma-derived Therapies Business (2018-2023)
11.9.5 LFB Recent Development
11.10 Grifols
11.10.1 Grifols Company Detail
11.10.2 Grifols Business Overview
11.10.3 Grifols Plasma-derived Therapies Introduction
11.10.4 Grifols Revenue in Plasma-derived Therapies Business (2018-2023)
11.10.5 Grifols Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.